Al B. Sure!™ is a Successful Transplant Recipient, multi-platinum singer, songwriter and producer, and Global Ambassador of New Jack Swing and R&B. He received a life-saving liver transplant at Houston Methodist Hospital in July 2022. He leads with transplant-equity advocacy, urging Medicare to cover blood tests that detect organ rejection.
Al B. Sure!™ is a Co-Founder of HEiTC, The Health Equity In Transplantation Coalition, and served as Executive Chairman (Retired). He retired from the coalition in August 2025. Through the coalition, he and coalition partners advocated for Medicare coverage of non-invasive post-transplant blood tests that can detect early signs of organ rejection, without tying that coverage to an invasive biopsy.
On February 29, 2024, and August 16, 2024, the Centers for Medicare & Medicaid Services published statements on coverage of these tests. A later local coverage determination, MolDX: Molecular Testing for Solid Organ Allograft Rejection (L40140), is effective for services performed on or after August 30, 2026. For current Medicare rules, see CMS. This official page is the record of Al B. Sure!™’s advocacy and current title; it is not medical or billing advice.
A Successful Transplant Recipient
Al B. Sure!™ received a life-saving liver transplant at Houston Methodist Hospital in July 2022. That experience shaped the work that followed: public advocacy so transplant patients can be monitored for organ rejection with non-invasive blood tests, and so Medicare’s coverage of those tests is stated in official terms patients, families, and the press can trust.
The Health Equity in Transplantation Coalition
Al B. Sure!™ is a Co-Founder of HEiTC, The Health Equity In Transplantation Coalition, and served as Executive Chairman (Retired). He retired from the coalition in August 2025. The coalition’s Congressional and transplant-equity record remains intact.
This official page uses his current title: he served as Executive Chairman (Retired). Earlier articles and announcements may still use a present-tense title; the wording on this page is the current official record.
Medicare coverage of post-transplant blood tests
Why these tests matter
Non-invasive blood tests can help monitor transplanted organs for early signs of rejection. Al B. Sure!™ leads with transplant-equity advocacy, urging Medicare to cover blood tests that detect organ rejection. This page is not medical advice. Patients and families should talk with their care team about the monitoring that is right for them.
The 2023–2024 coverage campaign
In December 2023, Al B. Sure!™ spoke at a Capitol Hill press conference during Honor the Gift Action Days. Transplant patients, physicians, and lawmakers asked federal officials to protect Medicare coverage of these tests.
On March 31, 2023, Medicare Administrative Contractors (MACs) issued a revised billing article for these tests. That CMS date is the official record of the billing-instruction change.
What CMS published in 2024
On February 29, 2024, the Centers for Medicare & Medicaid Services (CMS) published a statement on the current status of blood tests for organ transplant rejection. CMS said patients with transplanted hearts, lungs, or kidneys who meet Medicare’s local coverage criteria can continue to access these blood tests when medically necessary and ordered by a physician. CMS also said the MACs had updated the March 31, 2023 billing instructions, and that neither CMS nor the MACs had changed patients’ access to these tests.
On August 16, 2024, CMS published a further statement. CMS said the MACs were not finalizing the proposed Local Coverage Determination issued on August 10, 2023, and intended to issue a new LCD later. CMS again said that, at that time, neither CMS nor the MACs had changed coverage for these blood tests when ordered by physicians in medically appropriate circumstances. The August 16 statement used the same heart, lung, or kidney language, and listed circumstances that can include signs or symptoms of rejection; surveillance testing after a physician-assessed pretest; an indeterminate biopsy; use as a replacement for a biopsy when a qualified physician deems it clinically appropriate; and evaluation of the adequacy of immunosuppression.
This page closely paraphrases official CMS wording and links cms.gov. Al B. Sure!™ is a liver-transplant recipient. The 2024 CMS statements name heart, lung, and kidney in their coverage examples. This page does not treat those examples as an automatic description of liver-transplant coverage.
Where coverage stands now
A later Local Coverage Determination, MolDX: Molecular Testing for Solid Organ Allograft Rejection (L40140), is effective for services performed on or after August 30, 2026. The LCD provides limited coverage for molecular and proteomic tests used after solid organ transplantation when listed criteria are met.
In its published first-year surveillance-testing examples, the LCD names Kidney (6), Heart (12), and Lung (12). It also states: “Other transplant types will also be considered for coverage according to the criteria established in this LCD.” Liver is not named in those published examples. This page does not invent liver-specific testing numbers, and it does not say that the LCD excludes liver.
For current Medicare rules, patients and families should confirm coverage with their care team and with Medicare. This official page is not medical or billing advice, and it does not give case-level guidance.
Immunosuppressive drugs are a different benefit
Medicare coverage of immunosuppressive drugs is a separate benefit from the blood-test policy described above. That includes a Medicare Part B Immunosuppressive Drug (Part B-ID) option, available beginning January 1, 2023, for certain people whose Medicare was based on end-stage renal disease and ended 36 months after a successful kidney transplant, and who meet other official eligibility rules. See the official CMS and Medicare.gov pages for current rules. Do not confuse drug coverage with coverage of post-transplant blood tests.
Honors and ambassadorships
Award photographs are not shown on this page. Each honor links to its official or source page.
American Liver Foundation Houston Ambassador, Liver Life Walk (October 18, 2023)
On October 18, 2023, the American Liver Foundation announced Al B. Sure!™ as Houston Ambassador for its Liver Life Walk, in association with Houston Methodist Hospital. The Foundation published that announcement during Liver Awareness Month, presenting him as a Successful Transplant Recipient who would lead the public walk in Houston. The Liver Life Walk is a signature American Liver Foundation event, bringing together people affected by liver disease to raise awareness and funds for patient and family resources.
Official page: American Liver Foundation — Al B. Sure! launches national advocacy role as ambassador. Photographs on that official page are not copied or embedded here.
American Liver Foundation Transplant Trailblazer Award, National Legacy Gala at Gotham Hall (October 7, 2024)
On October 7, 2024, the American Liver Foundation honored Al B. Sure!™ with the Transplant Trailblazer Award at its National Legacy Gala, held at Gotham Hall in New York City. The Foundation recognized his work advancing health equity in transplantation after his July 2022 liver transplant, including advocacy for non-invasive blood tests that can detect early signs of organ rejection. The evening gathered patients, families, clinicians, and partners in support of the liver community.
Official pages: American Liver Foundation — Transplant Trailblazer Award; National Legacy Gala announcement, Gotham Hall. Photographs on those official pages are not copied or embedded here.
ILTS Celebration of Life (May 2, 2024)
On May 2, 2024, Al B. Sure!™ was honored among transplant recipients at the International Liver Transplantation Society’s Celebration of Life, presented as the Celebration of New Life: Raising Awareness for Transplantation for Liver Disease and Cancer Gala. The event was held at River Oaks Country Club in Houston during the Society’s 2024 congress and marked ILTS’s 30-year milestone. Proceeds were designated for the Society’s educational programs.
Official event record: ILTS Celebration of Life Gala (Wayback archive of 2024.ilts.org). No official event photograph is displayed on this page.
Excellence in Healthcare Advocacy, Attorney Ben Crump Equal Justice Now Awards (March 29, 2024)
On March 29, 2024, Al B. Sure!™ received the Excellence in Healthcare Advocacy honor at the Equal Justice Now Awards in Los Angeles, presented as Attorney Ben Crump’s Equal Justice Now Awards. The third annual ceremony was held at the Los Angeles Airport Marriott and recognized advocates whose work advanced justice and equality over the preceding year. The honor followed his public advocacy for transplant equity as a Successful Transplant Recipient and Co-Founder of HEiTC, The Health Equity In Transplantation Coalition.
Coverage: Los Angeles Sentinel (April 3, 2024). Photo source (text link only; the image is not shown and rights are not cleared for this site): Getty Images editorial #2124190946.
Official sources
- CMS: Statement on current status of blood tests for organ transplant rejection (February 29, 2024)
- CMS: MolDX Local Coverage Determination Statement (August 16, 2024)
- CMS: LCD L40140 — MolDX: Molecular Testing for Solid Organ Allograft Rejection (effective for services performed on or after August 30, 2026)
- CMS: Medicare Part B Immunosuppressive Drug Benefit
- Medicare.gov: End-stage renal disease
- American Liver Foundation: Al B. Sure! launches national advocacy role as ambassador (October 18, 2023)
- American Liver Foundation: Al B. Sure! receives Transplant Trailblazer Award at the 2024 National Legacy Gala
- American Liver Foundation: National Legacy Gala announcement, Gotham Hall (September 12, 2024)
- ILTS Congress Houston 2024 — Celebration of Life Gala (Wayback archive of 2024.ilts.org)
- Los Angeles Sentinel (April 3, 2024): Attorney Ben Crump’s Equal Justice Now Honors Justice and Equality Advocates
- Honor the Gift: Action Days 2023 Capitol Hill press conference
- Al B. Sure!™ official hub
- Al B. Sure!™ music and discography
Press Contact
Press inquiries: Press Contact, public business mail, 2368A Rice Blvd Suite 141, Houston TX 77005. A private phone number and a private email address are not listed here. No official booking or press email is published on albsure.net; this page uses the standing public business mail address, which is not a residence.
Official sites
- albsure.net — official hub
- albsure.net/music — official music and discography
- momdukes.club — official merch boutique
- The Mom Dukes Foundation — a related official site founded by Al B. Sure!™
Start at the official hub for accounts, radio, and other official links. momdukes.club is the official merch boutique. The Foundation site is linked here for brand context only.
FAQ
Who is Al B. Sure!™ as a transplant advocate?
Al B. Sure!™ is a Successful Transplant Recipient and a transplant-equity advocate urging Medicare to cover blood tests that detect organ rejection. He is a Co-Founder of HEiTC, The Health Equity In Transplantation Coalition, and served as Executive Chairman (Retired).
When and where did Al B. Sure!™ receive a liver transplant?
Al B. Sure!™ received a life-saving liver transplant at Houston Methodist Hospital in July 2022.
What is the Health Equity in Transplantation Coalition, and what was his role?
HEiTC, The Health Equity In Transplantation Coalition, is a transplant-equity coalition. Al B. Sure!™ is a Co-Founder of HEiTC and served as Executive Chairman (Retired). He retired from the coalition in August 2025. He is not the current Executive Chairman.
What Medicare issue did he advocate on?
He advocated for Medicare coverage of non-invasive post-transplant blood tests that can detect early signs of organ rejection, without tying that coverage to an invasive biopsy.
What did CMS officially say in 2024?
On February 29, 2024, CMS said patients with transplanted hearts, lungs, or kidneys who meet local coverage criteria can continue to access these blood tests when medically necessary and ordered by a physician, and that neither CMS nor the MACs had changed patients’ access. On August 16, 2024, CMS said the MACs were not finalizing the proposed LCD issued August 10, 2023, and that coverage was unchanged at that time. See the cms.gov statements linked on this page.
Where does Medicare coverage of these tests stand now?
Local Coverage Determination L40140, MolDX: Molecular Testing for Solid Organ Allograft Rejection, is effective for services performed on or after August 30, 2026. It provides limited coverage when listed criteria are met. Confirm current rules with a physician and with Medicare. This page is not medical or billing advice.
Is immunosuppressive-drug coverage the same issue?
No. Immunosuppressive-drug coverage is a different Medicare benefit, including a Part B-ID option for certain people whose Medicare was based on end-stage renal disease after a kidney transplant. See the official CMS and Medicare.gov pages linked on this page. Do not confuse that benefit with the blood-test policy.
Does the 2026 LCD list liver-transplant surveillance examples?
No. The published first-year surveillance examples name kidney, heart, and lung. The LCD also says other transplant types will be considered according to its criteria. This page does not say the LCD excludes liver, and it does not invent liver-specific testing numbers.